HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Sponsor
National Cancer Institute, Naples
Study ID
NCT00401427
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly.

Key Dates

First listed
Nov 20, 2006
Start date
Nov 30, 2002
Status verified
Jul 2012
Primary completion
Jun 30, 2006
Completion
Dec 31, 2006

Study Design

Enrollment
50 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

response rate

Related Studies